ArticleMolecular biology reports2025
Stigmasterol as a ptotential phytotherapeutic agent for benign prostatic hyperplasia: modulation of inflammation, oxidative stress, and apoptosis.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundBenign prostatic hyperplasia (BPH) is one of the most common urological diseases that cause lower urinary tract symptoms in aging men. Common treatments often have side effects, necessitating the investigation of safer therapeutic approach. Stigmasterol, a phytosterol found in various plants, has showed anti-inflammatory, antioxidant, and apoptotic regulatory properties, making it promising for BPH management.
objectiveThis study attempted to investigate the possible protective effects of stigmasterol in a BPH animal model. MATERIALS AND
methodsmale rats were divided randomly into three groups (n = 10): control group, BPH group, subcutaneously given testosterone dissolving in corn oil (3 mg/ kg body weight/ day) and BPH + Stigmasterol group, animals were orally administered Stigmasterol (100 mg/kg body weight/day) simultaneously with testosterone. After 21 days of treatments, the therapeutic potential of stigmasterol was evaluated using histological, biochemical and molecular analysis.
resultsStigmasterol significantly reduced the prostatic index (PI) and improved histological changes associated with BPH. Treatment with stigmasterol led to a prominent reduction in serum dihydrotestosterone levels, along with a significant decrease in prostatic tissue content of pro-inflammatory markers (TNF-α and IL-1β), proliferative biomarker PCNA expression, 5 α reductase, and androgen receptor expression. Additionally, stigmasterol efficiently lowered lipid peroxidation level (MDA), while enhancing the total antioxidant capacity. It also modulated apoptotic pathways by upregulating Bax expression and downregulating Bcl-2 in prostatic tissues. DISCUSSION AND
conclusionThe results demonstrate the promise of stigmasterol as a treatment for BPH via different pathways, including the inhibition of 5 α-reductase leading to reduce dihydrotestosterone levels; downregulating of androgen receptor signaling, contributing to its anti-androgenic effects; as well as antioxidant, anti-inflammatory, and anti-proliferative activities. Additionally, stigmasterol modulates apoptotic pathways, collectively contributing to the attenuation of BPH progression.
Indexed as
Identifiers
40690036What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.